CompletedNot Applicable

Efficacy of 200 IU OnabotulinumtoxinA in Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment

Turkey (Türkiye)60 participantsStarted 2020-01-01

Plain-language summary

This study aimed to assess the efficacy and safety of onabotulinumtoxinA (botulinum toxin type A) in patients with idiopathic overactive bladder (OAB) and urinary incontinence who had previously failed to respond to anticholinergic treatment. Additionally, we examined the impact of significant reductions in bladder wall thickness on therapeutic outcomes.

Who can participate

Age range16 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * overactive bladder urge incontinence Exclusion Criteria: * neurological and/or neurosurgical disorders, anticholinergic-naive patients, bladder cancer, bladder stone, interstitial cystitis, prostate cancer chronic prostatitis bladder outlet obstruction

What they're measuring

frequencies of urination, nocturia, incontinence episodes

Timeframe: 1 years

urgency,

Timeframe: 1 years

Trial details

NCT IDNCT06408051

SponsorHisar Intercontinental Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-01-31

View on ClinicalTrials.gov More Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment trials